Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 6, Issue 2, 2011, Pages 286-290

  Sirera, Rafael ^a,b   Bremnes, Roy M ^c,d   Cabrera, Andrea ^b   Jantus Lewintre, Eloísa ^b   Sanmartín, Elena ^b   Blasco, Ana ^b   Del Pozo, Nieves ^b   Rosell, Rafael ^e   Guijarro, Ricardo ^b   Galbis, José ^b   Sánchez, José Javier ^f   Camps, Carlos ^b  

^a UNIVERSITAT POLITÈCNICA DE VALÈNCIA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^c UNIVERSITY OF TROMSØ   (Norway)

^d UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^e HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^f UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

hTERT; Nonsmall cell lung cancer; NSCLC; Plasma; Prognostic factors; Telomerase

Indexed keywords

CIRCULATING DNA; CISPLATIN; DNA; DOCETAXEL; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME ACTIVE SITE; FEMALE; FOLLOW UP; GENDER AND SEX; HISTOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TELOMERASE; TUMOR MARKERS, BIOLOGICAL;

EID: 79551554979     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31820189a5     Document Type: Article

References (33)

1. Wang BG, Huang HY, Chen YC, et al. Increased plasma DNA integrity in cancer patients. Cancer Res 2003;63:3966-3968.
2. Silva JM, Silva J, Sanchez A, et al. Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival. Clin Cancer Res 2002;8:3761-3766.
3. Anker P, Stroun M. Tumor-related alterations in circulating DNA, potential for diagnosis, prognosis and detection of minimal residual disease. Leukemia 2001;15:289-291.
4. Leon SA, Shapiro B, Sklaroff DM, et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977;37:646-650.
5. Kopreski MS, Benko FA, Kwee C, et al. Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer. Br J Cancer 1997;76:1293-1299.
6. Kopreski MS, Benko FA, Borys DJ, et al. Somatic mutation screening: identification of individuals harboring K-ras mutations with the use of plasma DNA. J Natl Cancer Inst 2000;92:918-923.
7. Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001;61:1659-1665.
8. Pathak AK, Bhutani M, Kumar S, et al. Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool. Clin Chem 2006;52:1833-1842.
9. Stroun M, Anker P, Maurice P, et al. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 1989;46:318-322.
10. Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer-a survey. Biochim Biophys Acta 2007;1775:181-232.
11. Ramirez JL, Taron M, Balaña C, et al. Serum DNA as a tool for cancer patient management. Rocz Akad Med Bialymst 2003;48:34-41.
12. Ziegler A, Zangemeister-Wittke U, Stahel RA. Circulating DNA: a new diagnostic gold mine? Cancer Treat Rev 2002;28:255-271.
13. Sozzi G, Conte D, Leon M, et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 2003;21:3902-3908.
14. Altundag O, Altundag K, Altundag M. Free circulating DNA: good as a diagnostic marker in lung cancer? J Clin Oncol 2004;22:3201-3202.
15. Teare MD, Woll PJ. Genomic tests: unreliable for cancer? A focus on circulating DNA and lung cancer. Expert Rev Mol Diagn 2007;7:699-702.
16. Sozzi G, Conte D, Mariani L, et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res 2001;61:4675-4678.
17. Chen X, Bonnefoi H, Diebold-Berger S, et al. Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer. Clin Cancer Res 1999;5:2297-2303.
18. Fournié GJ, Courtin JP, Laval F, et al. Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours. Cancer Lett 1995;91:221-227.
19. Gautschi O, Bigosch C, Huegli B, et al. Circulating deoxyribonucleic acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol 2004;22:4157-4164.
20. Beau-Faller M, Gaub MP, Schneider A, et al. Plasma DNA microsatellite panel as sensitive and tumor-specific marker in lung cancer patients. Int J Cancer 2003;105:361-370.
21. Ludovini V, Pistola L, Gregorc V, et al. Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology. J Thorac Oncol 2008;3:365-373.
22. Camps C, Sirera R, Bremnes RM, et al. Quantification in the serum of the catalytic fraction of reverse telomerase: a useful prognostic factor in advanced non-small cell lung cancer. Anticancer Res 2006;26:4905-4909.
23. Bremnes RM, Sirera R, Camps C. Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up? Lung Cancer 2005;49:1-12.
24. Maebo A. [Plasma DNA level as a tumor marker in primary lung cancer]. Nihon Kyobu Shikkan Gakkai Zasshi 1990;28:1085-1091.
25. Xie GS, Hou AR, Li LY, et al. Quantification of plasma DNA as a screening tool for lung cancer. Chin Med J (Engl) 2004;117:1485-1488.
26. Fujita Y, Fujikane T, Fujiuchi S, et al. The diagnostic and prognostic relevance of human telomerase reverse transcriptase mRNA expression detected in situ in patients with nonsmall cell lung carcinoma. Cancer 2003;98:1008-1013.
27. Komiya T, Kawase I, Nitta T, et al. Prognostic significance of hTERT expression in non-small cell lung cancer. Int J Oncol 2000;16:1173-1177.
28. Coulet F, Blons H, Cabelguenne A, et al. Detection of plasma tumor DNA in head and neck squamous cell carcinoma by microsatellite typing and p53 mutation analysis. Cancer Res 2000;60:707-711.
29. Silva JM, Dominguez G, Garcia JM, et al. Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations. Cancer Res 1999;59:3251-3256.
30. Jung K, Stephan C, Lewandowski M, et al. Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancer. Cancer Lett 2004;205:173-180.
31. Lecomte T, Berger A, Zinzindohoué F, et al. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int J Cancer 2002;100:542-548.
32. van der Drift MA, Hol BE, Klaassen CH, et al. Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer. Lung Cancer 2010;68:283-287.
33. Sozzi G, Roz L, Conte D, et al. Plasma DNA quantification in lung cancer computed tomography screening: five-year results of a prospective study. Am J Respir Crit Care Med 2009;179:69-74.